Compare Invesco DB Commodity Index Tracking Fund (DBC) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco DB Commodity Index Tracking Fund vs Recursion Pharmaceuticals Inc — how do they compare? Invesco DB Commodity Index Tracking Fund trades at $32.93 (market cap $1.92B), while Recursion Pharmaceuticals Inc trades at $4.35 (market cap $2.14B). The key difference: Invesco DB Commodity Index Tracking Fund and Recursion Pharmaceuticals Inc are close in size by market cap, and Invesco DB Commodity Index Tracking Fund is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Invesco DB Commodity Index Tracking Fund for 60 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| DBC | RXRX | |
|---|---|---|
Market Cap | $1.92B | $2.14B |
Volume | 1,375,556 | 30,789,535 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $33.68 | $6.79 |
52-Week Low | $22.07 | $2.84 |
Typical Hold Time | 60 Days | 23 Days |
Enterprise Value | — | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DBC trades at $32.51, down 0.55% today, with a bullish technical signal from moving averages. The company reported $82.59M revenue and $22.38M net income for 2024, showing improved profitability with a 27.1% margin. Cash flow from operations was strong at $431.54M, though total assets declined from $2.7B in 2021 to $1.29B currently. Technical indicators show support at $32 and resistance at $33.
DBC demonstrates solid operational cash generation despite asset base contraction. The zero-debt balance sheet provides financial stability, but declining revenue from 2023's $108M raises growth concerns. Current valuation metrics remain undisclosed, requiring deeper analysis. The stock's technical strength suggests near-term upside potential if fundamental performance stabilizes.
RXRX trades at $4.255, down 0.35% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $644.76 million in 2025 on $74.26 million revenue, with a negative net income margin of -961.97%. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI announced September 21, 2026, and pipeline progress presented at the Morgan Stanley Healthcare Conference.
The outlook remains speculative, driven by AI-powered drug discovery potential and partnership milestones, but significant execution risk persists due to heavy losses and high cash burn. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for long-term platform value against near-term financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Invesco DB Commodity Index Tracking Fund
DBC is a diversified commodity ETF that tracks the DBIQ Optimum Yield Diversified Commodity Index. It invests in futures contracts for 14 heavily traded commodities, including crude oil, gold, and corn, while optimizing for yield and roll costs.
Read more on DBC →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
